ClinicalTrials.gg
RecruitingNCT04512456Updated Mar 27, 2026

Cardiovascular Responses to Exercise in People Living With HIV/AIDS: Effects of Exercise Training

An interventional study of Exercise training in HIV Infections, sponsored by Instituto Nacional de Cardiologia de Laranjeiras. Recruiting at 1 site in Brazil. Open to participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Instituto Nacional de Cardiologia de Laranjeiras · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in HIV Infections with a site in Brazil — 12 open to participants now, 17 under way, 5 of them phase 3. HIV Infections · Brazil.

Planned enrollment
88th of 116
63 · median 255
Started
2024
with 2 others
No phase
16 of 142
4 open now
Primary completion
2026-12
later than 7 of 16 live
Registered
121st of 142
by date

Among the 142 studies in HIV Infections with a site in Brazil, this one is the 88th largest by planned enrollment of the 116 interventional ones that give a count, is one of 3 that started in 2024, is one of 16 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 121st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

12 of the 142 studies in HIV Infections with a site in Brazil are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 30 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in HIV Infections with a site in Brazil, or all of them as a file.
02

Study summary

Patients living with HIV (PLWHIV) have compromised muscle metaboreflex, which can cause exercise intolerance. This randomized controlled clinical trial will verify the effects of regular exercise on autonomic and hemodynamic responses to muscle ergoreflex activation in these patients. PLWHIV without regular physical exercise will be randomly assigned into an exercise training or a control group. The exercise training group will undergo regular physical exercise during 12 weeks (60-min session performed 3 times/wk with moderate intensity), while the control group will keep inactive. Another group consisted of inactive HIV-uninfected group will be included. The primary endpoints will be blood pressure and autonomic markers in response to the Stroop Color-Word Test and the activation of muscle ergoreflex, by means of the post-exercise circulatory arrest (PECA), which will be performed with and without the topical application of a capsaicin-based analgesic balm. Secondary endpoints will include heart rate, peripheral vascular resistance, stroke volume, cardiac output, blood lactate concentration, anthropometrics, and handgrip strength. The active and inactive PLWHIV groups will be evaluated before and after the exercise training, while the healthy group only at baseline.

Read the detailed description

HIV-infection is associated to a reduced maximal cardiac output and blunted pressor reflex response to static handgrip exercise, which are suggestive of impaired ergoreflex activation. An abnormal ergoreflex activation may lead to exercise intolerance and increases in cardiovascular risk. Despite the importance of therapeutic strategies in reducing the cardiovascular risk among patients living with HIV, exercise-related effects on ergoreflex sensitivity in these population have not been previously investigated.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of HIv infection for at least 5 years;
  • use of combined antiretroviral therapy for at least 3 years;
  • asymptomatic and free from opportunistic diseases at enrollment.

Exclusion criteria

Exclusion Criteria:

  • regular physical exercise;
  • malnutrition;
  • presence of coronary artery disease, ischemic diseases, pulmonary disease, diabetes, Chagas disease, tuberculosis, heart failure, hypertension;
  • using pacemakers and/or antidepressant, antiarrhythmic or antihypertensive medication, especially beta-blockers.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Active HIV-infected patients

    Exercise training

    Behavioral: Exercise training

  • No intervention
    Inactive HIV-infected patients

    No intervention.

  • No intervention
    Healthy subjects

    No intervention.

Interventions

  • BehavioralExercise training

    Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.

06

What researchers measure

Primary outcomes

  1. Change from Baseline Blood Pressure at 3 months

    Blood pressure will be assessed by a digital sphygmomanometer.

    Time frame: Baseline and 3 months of follow-up

  2. Change from Baseline Heart Rate Variability at 3 months

    Heart rate variability will be assessed by a heart rate monitor.

    Time frame: Baseline and 3 months of follow-up

Secondary outcomes

  1. Change from Baseline Heart Rate at 3 months

    Heart rate will be evaluated beat-to-beat by means of a heart rate monitor.

    Time frame: Baseline and 3 months of follow-up

  2. Change from Baseline Peripheral Vascular Resistance at 3 months

    Peripheral Vascular Resistance will be evaluated by photpletismography.

    Time frame: Baseline and 3 months of follow-up

  3. Change from Baseline Stroke Volume at 3 months

    Stroke Volume will be evaluated by photoplethysmography.

    Time frame: Baseline and 3 months of follow-up

  4. Change from Baseline Cardiac Output at 3 months

    Cardiac Output will be evaluated by photoplethysmography.

    Time frame: Baseline and 3 months of follow-up

  5. Change from Baseline Blood Lactate at 3 months

    Blood Lactate will be determined by the YSL 2700 analyzer.

    Time frame: Baseline and 3 months of follow-up.

  6. Change from Baseline Anthropometric markers at 3 months

    Anthropometric markers will be determined by a digital scale and wall-mounted stadiometer.

    Time frame: Baseline and 3 months of follow-up.

  7. Change from Baseline handgrip maximal voluntary contraction at 3 months

    Handgrip maximal voluntary contraction will be assessed using a hydraulic handgrip dynamometer.

    Time frame: Baseline and 3 months of follow-up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gama G, Dos Santos Rangel MV, de Oliveira Coelho VC, Paz GA, de Matos CVB, Silva BP, Lopes GO, Lopes KG, Farinatti P, Borges JP. The effects of exercise training on autonomic and hemodynamic responses to muscle metaboreflex in people living with HIV/AIDS: A randomized clinical trial protocol. PLoS One. 2022 Mar 18;17(3):e0265516. doi: 10.1371/journal.pone.0265516. eCollection 2022. PubMed 35303017 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 28 months is close to that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 13, 2020
StartActual
Aug 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04512456
Lead sponsor
Instituto Nacional de Cardiologia de Laranjeiras
Collaborators
Rio de Janeiro State University
Responsible party
Juliana Pereira Borges (Professor, Rio de Janeiro State University) — Principal investigator
First posted
Aug 13, 2020
Start date
Aug 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Juliana P Borges, Dr.
Contact
julipborges@gmail.com
+552123340775
Gabriel S Gama
Contact
profgabrielgama@gmail.com
+552123340775
Julana P Borges, Dr
principal investigator · Rio de Janeiro State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion